AbbVie's 2025 Results: Skyrizi & Rinvoq Drive Growth, Positive 2026 Outlook

SEC 8-K Filing Notice

Company: AbbVie Inc. (ABBV) Filing Date: 2026-02-04 Accession Number: 0001551152-26-000004

Items Filed

Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Summary

AbbVie reported its full-year and fourth-quarter 2025 financial results, showcasing strong growth driven by its immunology portfolio, particularly Skyrizi and Rinvoq. Full-year net revenues reached $61.160 billion, an 8.6% increase, with adjusted diluted EPS at $10.00. The company's immunology and neuroscience portfolios demonstrated significant growth, offsetting declines in Humira revenues due to loss of exclusivity. AbbVie also provided a 2026 adjusted diluted EPS guidance range of $14.37 to $14.57, excluding potential IPR&D expenses.

Key Takeaways

Full-year net revenues increased 8.6% to $61.160 billion, driven by Skyrizi and Rinvoq.
Immunology and Neuroscience portfolios showed strong growth, offsetting Humira revenue decline.
FDA approved Epkinly for relapsed/refractory follicular lymphoma, marking the third indication for the drug.
AbbVie submitted applications to the FDA and EMA for Rinvoq in vitiligo and Aquipta for acute migraine treatment.
AbbVie projects 2026 adjusted diluted EPS between $14.37 and $14.57.

Analysis

AbbVie's performance demonstrates its successful diversification strategy following Humira's loss of exclusivity. The strong growth of Skyrizi and Rinvoq in immunology, along with Vraylar and Botox in neuroscience, indicates a robust product portfolio. The company's active pursuit of new indications for existing drugs, such as Rinvoq and Aquipta, and the FDA approval of Epkinly, highlight its commitment to innovation and expanding its market reach. The licensing agreement with RemeGen for RC148 and the acquisition of West Pharmaceutical Services' device manufacturing facility further strengthen AbbVie's pipeline and manufacturing capabilities, positioning it for continued growth.

This post was automatically generated from an SEC 8-K filing.